Facts and Figures in R&D
No company in the world invests more than we do in the quest for innovative healthcare solutions. In 2012 Roche spent over 8 billion Swiss francs on research and development and employed over 18,000 people in this field.
More than 300,000 patients are currently enrolled in over 2,200 clinical trials involving investigational or currently marketed Roche Group medicines.
% of sales
% of sales
* Constant exchange rates (average full-year 2011).
|% of sales|
Pharmaceuticals and Diagnostics Divisions collaborated on more than 200 projects and a unique R&D network model and strong alliances with companies, universities and research institutions worldwide give our scientists broadest access to innovation.
Roche has Research centers around the world with scientists passionate about discovering medicines to meet the unmet medical needs of patients. Even more scientists and physicians around the world design and conduct preclinical and clinical trials to transform those promising compounds into clinically differentiated medicines.
The Research and Development sites focus on specific disease areas that are exploring multiple therapeutic modalities and using numerous strategic technologies to conduct R&D from early discovery and translational medicine to preclinical and clinical development. They are:
|Basel, Switzerland (R&D)||Metabolics and Central Nervous System|
|Nutley (NJ), USA (R&D)||Oncology, Inflammation, Virology and Metabolics,|
|Penzberg, Germany (R)||Protein Therapeutics and Stem Cells|
|Schlieren, Switzerland (R)||Protein Therapeutics|
|Shanghai, China (R&D)||Research and Clinical Development|
|South San Francisco (CA), USA (R&D)||Oncology, Inflammation, Virology, Ophtalmology|
|Strasbourg, France (R)||Institute of Translational and Experimental Medicine|
|Sydney, Australia (D)||Clinical Development Operations|
|Welwyn, United Kingdom (R&D)||Pharmaceutical Development|